• Men and women ≥ 50 years of age at Screening.

• Diagnosis of Geographic Atrophy secondary to d-AMD

• Have Best Corrected Visual Acuity (BCVA) equal to or less than 20/200 Snellen (ETDRS letter score ≤ 35) in the study eye at screening.

∙ Phase 1 ≤ 20/200 and

‣ Phase 2a ≥ 20/64 (ETDRS letter score 60) in the study eye at Screening.

• Vision in the unoperated eye must be better or equal to vision in the study eye.

• Willing, committed, and able to return for ALL clinic visits and complete all study related procedures.

• Be medically suitable to undergo anesthesia, vitrectomy and subretinal injection in the opinion of the Investigator.

• Be medically suitable for immunosuppression therapy in accordance with the requirements of this protocol in the opinion of the Investigator.

• Able to read (or if unable to read due to visual impairment, be read to verbatim by the person administering the informed consent or a family member) and understand, and willing to sign the informed consent form (ICF)

• Willing to provide signed Informed Consent prior to any procedures being performed at Visit 1, Screening.

⁃ Negative for HIV, HbsAg, HCV, TB

⁃ The GA lesion must meet the following criteria as determined by the central reading center's assessment of Fundus Autofluorescence (FAF) imaging at screening:

• Total GA area must be ≥ 1.25 and ≤ 17.5 mm2 (0.5 and 7 disk areas \[DA\] respectively)

∙ The entire GA lesion must be completely visualized on the macula centered image and must be able to be imaged in its entirety and not contiguous with any areas of peripapillary atrophy.

∙ At least one of the lesions has to be sub-foveal.